By Sabela Ojea
Shares of BridgeBio Pharma climbed 14% to $20.85 in after-hours Friday trading after the company said it would share results from the latest phase of its transthyretin amyloid cardiomyopathy heart disease study.
The commercial-stage biopharmaceutical company is set to make public findings from the phase 3 ATTRibute-CM clinical study during an investor call on Monday.
Transthyretin amyloid cardiomyopathy is a rare cause of restrictive cardiomyopathy.
Write to Sabela Ojea at sabela.ojea@wsj.com
Read the full article here